Firstly, we have learned that ATM gene mutations are correlated with specific clinical characteristics of BC such as high risk of ER-positive BC, grade two or three tumors, lymph node involvement, and HER2-positivity as well as the development of a contralateral breast tumor in patients resistant to radiotherapy. This evidence concerns the gene ERBB2 and breast cancer.